

# Margaret Stanley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5681495/publications.pdf>

Version: 2024-02-01

54  
papers

3,075  
citations

218381

26  
h-index

205818

48  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3593  
citing authors

#	ARTICLE	IF	CITATIONS
1	HPV prevention and control – The way forward. Preventive Medicine, 2022, 156, 106960.	1.6	15
2	Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. British Journal of Cancer, 2021, 124, 831-841.	2.9	39
3	Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes. Vaccine, 2021, 39, 4419-4422.	1.7	3
4	Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report. BMC Proceedings, 2021, 15, 16.	1.8	9
5	Host defence and persistent human papillomavirus infection. Current Opinion in Virology, 2021, 51, 106-110.	2.6	7
6	Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. Journal of Infectious Diseases, 2019, 219, 41-49.	1.9	9
7	HPV vaccines: alternative dosage schedules. Expert Review of Vaccines, 2019, 18, 1309-1316.	2.0	8
8	The Cape Town declaration on human papillomavirus related disease. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 59-60.	4.5	1
9	HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine, 2018, 36, 4759-4760.	1.7	18
10	Reply to San Giorgi and Dikkers. Journal of Infectious Diseases, 2018, 217, 1506-1506.	1.9	0
11	Realities of alternative HPV vaccination schedules. Salud Publica De Mexico, 2018, 60, 617.	0.1	0
12	Anal cancer in women: are we appropriately identifying the risks?. Sexually Transmitted Infections, 2017, 93, 455-456.	0.8	1
13	Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open, 2017, 7, e015413.	0.8	9
14	Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160268.	1.8	48
15	Human Papillomavirus Vaccines. , 2016, , 245-263.		14
16	HPV vaccines: how many doses are needed for protection?. Future Virology, 2016, 11, 283-292.	0.9	0
17	Preventing cervical cancer and genital warts – How much protection is enough for HPV vaccines?. Journal of Infection, 2016, 72, S23-S28.	1.7	13
18	Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open, 2016, 6, e011205.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 30-38.	1.4	31
20	Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 768-772.	1.4	43
21	Immunology of HPV Infection. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 195-200.	0.3	10
22	Human Papilloma Virus Vaccines. , 2015, , 271-289.		1
23	HPV vaccination in boys and men. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2109-2111.	1.4	89
24	HPV vaccination in boys and men. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2106-2108.	1.4	16
25	HPV vaccination. <i>BMJ, The</i> , 2014, 349, g4783-g4783.	3.0	12
26	Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. <i>Vaccine</i> , 2014, 32, 725-732.	1.7	79
27	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, I1-I31.	1.7	261
28	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	1.7	272
29	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, F1-F31.	1.7	40
30	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, G1-G31.	1.7	33
31	Perspective: Vaccinate boys too. <i>Nature</i> , 2012, 488, S10-S10.	13.7	46
32	Human Papillomavirus Vaccines "Immune Responses. <i>Vaccine</i> , 2012, 30, F83-F87.	1.7	136
33	European Consensus Statement on "HPV Vaccination and Colposcopy". <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 309-315.	0.9	7
34	Prospects for new human papillomavirus vaccines. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 70-75.	1.3	34
35	Pathology and epidemiology of HPV infection in females. <i>Gynecologic Oncology</i> , 2010, 117, S5-S10.	0.6	347
36	Potential mechanisms for HPV vaccine-induced long-term protection. <i>Gynecologic Oncology</i> , 2010, 118, S2-S7.	0.6	47

#	ARTICLE	IF	CITATIONS
37	HPV - immune response to infection and vaccination. <i>Infectious Agents and Cancer</i> , 2010, 5, 19.	1.2	161
38	Early age of sexual debut: a risky experience. <i>Journal of Family Planning and Reproductive Health Care</i> , 2009, 35, 118-120.	0.9	11
39	Immunobiology of HPV and HPV vaccines. <i>Gynecologic Oncology</i> , 2008, 109, S15-S21.	0.6	195
40	Immunobiology of Human Papillomavirus Infection and Vaccination - Implications for Second Generation Vaccines. <i>Vaccine</i> , 2008, 26, K62-K67.	1.7	52
41	Monitoring HPV vaccination. <i>Vaccine</i> , 2008, 26, A24-A27.	1.7	21
42	HPV vaccines: are they the answer?. <i>British Medical Bulletin</i> , 2008, 88, 59-74.	2.7	13
43	The epidemiology and burden of HPV disease. <i>Nursing Times</i> , 2008, 104, 38-40.	0.2	0
44	HPV vaccines: where are we now?. <i>Journal of Family Planning and Reproductive Health Care</i> , 2007, 33, 227-229.	0.9	4
45	Prophylactic HPV vaccines. <i>Drugs of Today</i> , 2007, 43, 737.	0.7	6
46	Immune responses to human papillomavirus. <i>Vaccine</i> , 2006, 24, S16-S22.	1.7	431
47	Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. <i>Vaccine</i> , 2006, 24, S106-S113.	1.7	199
48	Prophylactic HPV vaccines. <i>Journal of Clinical Pathology</i> , 2006, 60, 961-965.	1.0	39
49	Chapter 17: Genital Human Papillomavirus Infections--Current and Prospective Therapies. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 117-124.	0.9	73
50	Early genetic events in HPV immortalised keratinocytes. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 72-79.	1.5	36
51	The Interaction between Human Papillomavirus Type 16 E1 and E2 Proteins is Blocked by An Antibody to the N-Terminal Region of E2. <i>FEBS Journal</i> , 1995, 229, 517-525.	0.2	35
52	Immunocytochemical characterization of large granular lymphocytes in normal cervix and HPV associated disease. <i>Journal of Pathology</i> , 1991, 165, 75-80.	2.1	37
53	Cultured keratinocyte grafts are recognized, but not rejected by CD8+ T cells in vivo. <i>European Journal of Immunology</i> , 1989, 19, 1031-1035.	1.6	9
54	Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and E1-ras. <i>International Journal of Cancer</i> , 1988, 42, 232-238.	2.3	41